Weekly Digest – July 2025 Weekly Digest – July 2025 02 July 2025: Biokin, having landed BMS deal, posts Phase 3 cancer win for bispecific ADC Biokins Phase 3 trial of its bispecific ADC, Izalontamab brengitecan (iza-bren), met at least […]
Weekly Digest – July 2025 Weekly Digest – July 2025 03 July 2025: Akeso’s first bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials, strengthening leadership in ‘IO+ADC’ 2.0 strategy Akeso has dosed the first patient in the Phase 1 clinical trial […]
Weekly Digest – June 2025 Weekly Digest – June 2025 23 June 2025: DATROWAY approved in the U.S. as first TROP2 directed therapy for patients with previously treated advanced EGFR-mutated non-small cell lung cancer DATROWAY (datopotamab deruxtecan-dlnk) received accelerated approval in […]
Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: MediLink announces YL201 granted Breakthrough Therapy Designation by FDA The U.S. FDA has granted Breakthrough Therapy Designation to YL201, a B7H3-targeted ADC developed by MediLink Therapeutics, for […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Huadong Medicine’s FGFR2b target ADC innovative drug HDM2020 China IND was approved by the NMPA Zhongmei Huadong, a subsidiary of Huadong Pharmaceutical, received NMPA approval to initiate […]
Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: Dong-A ST files IND for Phase 1 clinical trial of ADC candidate for cancer Dong-A ST’s ADC subsidiary, Aptis, has submitted an IND application in South Korea […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Bio-Thera Solutions announce first patient dosed in Phase 3 clinical trial for BAT8006, an Antibody Drug Conjugate targeting folate receptor α for the treatment of platinum-resistant ovarian […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Corbus Pharmaceuticals announces first patient dosed with its Nectin-4 targeting ADC CRB-701 in combination with pembrolizumab Corbus Pharmaceuticals has dosed the first participant in the PD-1 combination […]
Weekly Digest – June 2025 Weekly Digest – June 2025 17 June 2025: FDA grants orphan drug designation to Medicovestor’s first-in-class ADC for pancreatic cancer The FDA has granted Orphan Drug Designation to Medicovestor’s lead candidate, ADoBind MC001, for treating […]
Weekly Digest – June 2025 Weekly Digest – June 2025 17 June 2025: Boan receives FDA IND clearance for Its CD228-directed ADC Boan Biotech received FDA clearance to begin clinical trials in the U.S. for BA1302, a novel CD228-targeting ADC […]
